Merck gets FDA nod for allergy drug


An FDA advisory committee panel unanimously agrees the available data support the efficacy and safety of Merck's (MRK) GRASTEK for treating pollen allergy in those aged 5 and up. The panel did recommend post-approval studies for those aged 5-11, citing some side effects.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs